Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development

Jennifer Pierson; Anthony Bahinski; Brian R. Berridge; Daniel Bramham; Todd Bourcier; Khuram W. Chaudhary; Sandy Eldridge; Yasunari Kanda; William B. Mattes; James M. Oliphant; Li Pang; Alex Savtchenko; Jeffrey Siegel; Natalie E. Simpson; Chengyi Tu; Ronald L. Wange; Joseph C. Wu; Xi Yang

doi:10.1177/10915818251375348

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Expert workshop report highlights the utility of novel cardiac screening models in preclinical drug safety, indicating potential to reduce drug attrition and animal testing.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pierson et al. (2025) studied this question.

synapsesocial.com/papers/6a98dacc55a4ce6507f59bd2 https://doi.org/10.1177/10915818251375348

View Full Paper

Ask AI

Bookmark

Implication

Expert workshop report highlights the utility of novel cardiac screening models in preclinical drug safety, indicating potential to reduce drug attrition and animal testing.

Abstract

No abstract yet. The journal hasn't published one we can show.

Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading